Acute rejection after kidney transplantation

Slides:



Advertisements
Similar presentations
Immunology of Renal Transplant
Advertisements

Acute cellular and humoral rejection
Transplant Immunology & Renal Allograft Rejection
Significance of the total i-score
Case no. 7. Eva Honsova Institute for Clinical and Experimental Medicine Pathology Department Prague, Czech Republic
Chronic vascular injury of the kidney allograft: The contribution of rejection Heinz Regele Heinz Regele Department of Pathology Innsbruck Medical University.
Michael Mengel Department of Laboratory Medicine and Pathology
Kidney allografts with biopsy features of chronic mixed rejection reflect poorer survival than those with pure chronic antibody-mediated rejection D. Dobi,
The Value of Zero-Hour Implantation Biopsies Volker Nickeleit Nephropathology Laboratory, Department of Pathology The University of North Carolina, Chapel.
PATHOLOGIC DIAGNOSIS OF ANTIBODY-MEDIATED REJECTION (AMR) Histopathologic findings Immunopathologic findings Immunohistochemistry on paraffin sections.
The value of protocol biopsies in renal allografts Gordana Petrusevska Skopje, Macedonia Gordana Petrusevska Skopje, Macedonia.
The Significance of C4d Staining with Minimal Histologic Abnormalities
Slide 1PUBLICATIONS Racusen/Solez meeting report for AJT. Racusen/Solez meeting report for AJT. Manuscript on antibody-mediated rejection. Manuscript on.
Pancreas Transplant Pathology: Controversial Lesions Lois J. Arend PhD, MD University of Cincinnati Department of Pathology.
Sum Scores & Components’ Scores Chronic Scores Acute Rejection Scores Lillian W. Gaber University of Tennessee.
Calcineurin Inhibitor Toxicity In Kidney Allograft Protocol Biopsies Neeraja Kambham M.D. Stanford University.
Journal Reading Present by Dr. 陳志榮. The Banff 97 Working Classification of Renal Allograft Pathology Racusen LC, Solez K, Colvin RB, Bonsib.
Immune Profiling in Renal Transplantation: Biopsy Correlations with Urine and Plasma PCR Studies Surya V. Seshan, T. Muthukumar, D, Dadhania, M. Suthanthiran.
Schemas for Histopathological Diagnosis of Rejection: Kidney Schemas for Histopathological Diagnosis of Rejection: Kidney Kim Solez, M.D.
Summaries by Session Chairs of Banff 2003: C4d scoring/Ab mediated reject. - Bob Colvin GeneAnalysis/Microarrays/Tubulitis/Tolerance - Lorraine Racusen.
MONOCYTE/MACROPHAGES AND C4d IN RENAL ALLOGRAFTS Alex Magil, MD.
Slide Seminar Drugs and Kidney Case 3 Heinz Regele Department of Pathology.
Sum Scores and Scores of Individual Components in Clinical Practice and Clinical Trials Lillian W. Gaber University of Tennessee.
Peritubular Capillary Inflammatory Cell Accumulation Scoring
Rejection Associated Glomerular Lesions Part 2 M.J. Mihatsch, H. Hopfer, F. Gudat, V. Nickeleit.
C4d - staining: Comparison of methods C. Seemayer, A. Gaspert, M. Mihatsch.
Transplantation Immunology Laura Stacy March 22, 2006.
Current problems in kidney transplantation: Clinical point of view
Agnieszka Perkowska-Ptasinska1, M. Ciszek, A.L. Urbanowicz, L. Paczek,
REBIN TITUS Clinical Case Conference. Presenting history 44-year-old, Hispanic male with a history of ESRD, most likely secondary to his diabetes and.
© 2014 Direct One Communications, Inc. All rights reserved. 1 Finding Solutions to Improving Long-Term Outcomes Imran Javed, MD University of Washington.
Renal Transplantation Basic Science Review 11/23/05.
Monitoring HLA-specific antibodies
Protein casts, nodular glomerulosclerosis in a graft biopsy samples Agnieszka Perkowska-Ptasinska Transplantation Institute, Medical University of Warsaw,
Section 3 Transplant Rejection
Pathology of Kidney and the Urinary tract
Severe vascular lesions and poor functional outcome
Interactive Case Discussion Case 6 Dr Megha S Uppin Asst Prof Dept of Pathology Nizam’s Institute of Medical Sciences Hyderabad.
Kidney transplant case Niels Marcussen Hans Dieperink Odense University Hospital.
Humoral rejection: What the pathologist needs to know Humoral rejection: What the pathologist needs to know Heinz Regele Heinz Regele Clinical Institute.
Pathology of Kidney and the Urinary tract Dr. Amar C. Al-Rikabi Dr. Hala Kasouf Kfouri.
Prognostic significance of C4-positive vs. negative rejection Heinz Regele Heinz Regele Department of Pathology Innsbruck Medical University Heinz Regele.
ANTIBODY MEDIATED REJECTION (HUMORAL REJECTION)
Laboratory Handling of the Renal Biopsy Dr. Issam Francis Kuwait 4 th SSN Annual International Conference, Riyadh, April 2009.
C4d in pancreas transplant biopsies: the Leiden experience Ingeborg Bajema Ingeborg Bajema Ingeborg Bajema.
TRANSPLANTATION & tissue rejection
Autoimmune Diseases How Do the Immune Cells of the Body Know What to Attack and What Not To Attack ?
U # Chronic renal failure – secondary to IgA nephropathy. Deceased donor kidney transplant – August Complicated by delayed graft.
Reference: Gloor J, Stegall MD
Acute antibody-mediated rejection
Antibody-Mediated Rejection in Renal transplantation
Pathology of Renal Transplantation
Donor Matching of Kidney Transplantation
U # LRD kid tx March/99 Original Dis IgA.
Mechanism and Treatment of Antibody-Mediated Rejection
Anand Yuvaraj International Transplant Fellow
KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients 순천향대학교 서울병원 신장내과 R2 김윤석.
T. N. Nikonenko, A. V. Trailin and A. S. Nikonenko
Persistent rejection of peritubular capillaries and tubules is associated with progressive interstitial fibrosis  Akira Shimizu, Kazuhiko Yamada, David.
Transplantation Immunology
Volume 67, Issue 1, Pages (January 2005)
Volume 87, Issue 1, Pages (January 2015)
Kidney Transplant Dr. Basu.
An Observational Study on Thrombotic Microangiopathy in Renal Transplant Recipients - A Tertiary Care Centre Experience. Dr Sarang Vijayan Senior Resident.
Volume 84, Issue 4, Pages (October 2013)
Transplantation Immunology
Akira Shimizu, Kazuhiko Yamada, David H. Sachs, Robert B. Colvin 
Post-transplant membranous glomerulonephritis as a manifestation of chronic antibody-mediated rejection Hyeon Joo Jeong, Beom Jin Lim, Myoung Soo Kima,
Volume 86, Issue 3, Pages (September 2014)
Volume 61, Issue 4, Pages (April 2002)
Presentation transcript:

Acute rejection after kidney transplantation Pr Lionel ROSTAING Département de Néphrologie et Transplantation d’Organes (DNTO) CHU Toulouse-Rangueil, France rostaing.l@chu-toulouse.fr Tbilisi, April 8th2016

Prevalence of acute rejection: 10 to 20% [acute cellular rejection : 90% antibody-mediated rejection: 10%] -2-

Hyperacute rejection It is mediated by preformed circulating antibodies that do bind complement : they can be directed against Donor HLA antigens ABO antigens (in the setting of ABO incompatible kidney transplantation) Xeno-antigens. Complement activation results in platelet aggegation and ultimately vascular thrombosis organ necrosis This type of acute rejection should NEVER be observed -3-

Homoral/vascular rejection It is mediated by alloantibody (ies) already present at transplantation but however, at very low titer : thereby the cross-match (microlymphocytotoxicity) is negative. Conversely, these alloantibody (ies) can be synthetized at posttransplant anamnestic response). Anti-HLA alloantibody Anti-endothelial cell antibody Mostly observed in patients transfused in the past or in women (pregnancy, miscarriage) Histology : Vascular lesions (endarteritis ; C4d deposits on vascular walls) Withoit specific treatment results in organ necrosis This type of rejection represents less than 10% of acute rejections. -4-

Acute cellular rejection Acute cellular rejection : this is the most frequent acute rejection type This is a T-cell mediated process Differed process (a few days to a few months) If no treatment is implemented, this will result in organ destruction Acute cellular rejection occurs in 10 to 15% of kidney transplant patients -5-

Targets of acute rejection Kidney  tubular cells, endothelium (glomeruli) Prevalence of acute cellular rejection : 10 to 15% Prevalence of acute humoral rejection : a few % What are the mediators of acute rejection? T activated cytotoxic lymphocytes (CD8+, CD45 RO+, DR+, Perforine+, granzyme B+, Fas L+) Donor-specific alloantibodies (DSA); complement activation. -6-

Rejection description according to Banff classification -7-

Banff 07 diagnostic categories for renal allograft biopsies (1); revised in 2013 T-cell-mediated rejection (TCMR)  Acute T-cell-mediated rejection (Type/Grade:) IA. Cases with significant interstitial infiltration (>25% of parenchyma affected, i2 or i3) and foci of moderate tubulitis (t2) IB. Cases with significant interstitial infiltration (>25% of parenchyma affected, i2 or i3) and foci of severe tubulitis (t3) IIA. Cases with mild-to-moderate intimal arteritis (v1) IIB. Cases with severe intimal arteritis comprising >25% of the luminal area (v2) III. Cases with ‘transmural’ arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic inflammation (v3)  Chronic active T-cell-mediated rejection ‘chronic allograft arteriopathy’ (arterial intimal fibrosis with mononuclear cell infiltration in fibrosis, formation of neo-intima) Solez K et al. Am J Transplant 2008;8:753-760 -8-

Banff 07 diagnostic categories for renal allograft biopsies (2); revised in 2013 Borderline changes: ‘Suspicious’ for acute T-cell-mediated rejection This category is used when no intimal arteritis is present, but there are foci of tubulitis (t1, t2 or t3) with minor interstitial infiltration (i0 or i1) or interstitial infiltration (i2, i3) with mild (t1) tubulitis Solez K et al. Am J Transplant 2008;8:753-760 -9-

Banff 07 diagnostic categories for renal allograft biopsies (3); revised in 2013 Acute/active AMR; all three features must be present for diagnosis 1. Histologic evidence of acute tissue injury, including one or more of the following: Microvascular inflammation (g > 0 and/or ptc > 0) Intimal or transmural arteritis (v > 0) Acute thrombotic microangiopathy, in the absence of any other cause Acute tubular injury, in the absence of any other apparent cause 2. Evidence of current/recent antibody interaction with vascular endothelium, including at least one of the following: Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or C4d > 0 by IHC on paraffin sections) At least moderate microvascular inflammation ([g + ptc] ≥ 2) Increased expression of gene transcripts in the biopsy tissue indicative of endothelial injury, if thoroughly validated 3. Serologic evidence of donor-specific antibodies (DSAs) (HLA or other antigens) Haas M et al. Am J Transplant 2014;14:272-283 -10-

Banff 07 diagnostic categories for renal allograft biopsies (4); revised in 2013 Chronic, active AMR; all three features must be present for diagnosis 1. Morphologic evidence of chronic tissue injury, including one or more of the following : Transplant glomerulopathy (TG) (cg > 0), if no evidence of chronic thrombotic microangiopathy> 0) Severe peritubular capillary basement membrane multilayering (requires EM) Arterial intimal fibrosis of new onset, excluding other causes 2. Evidence of current/recent antibody interaction with vascular endothelium, including at least one of the following: Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or C4d > 0 by IHC on paraffin sections) At least moderate microvascular inflammation ([g + ptc] ≥ 2) Increased expression of gene transcripts in the biopsy tissue indicative of endothelial injury, if thoroughly validated 3. Serologic evidence of DSAs (HLA or other antigens) Haas M et al. Am J Transplant 2014;14:272-283 -11-

Banff 07 diagnostic categories for renal allograft biopsies (5); revised in 2013 Interstitial fibrosis and tubular atrophy, no evidence of any specific etiology (may include nonspecific vascular and glomerular sclerosis, but severity graded by tubulointerstitial features)  Grade : I. Mild interstitial fibrosis and tubular atrophy (<25% of cortical area) II. Moderate interstitial fibrosis and tubular atrophy (26–50% of cortical area) III. Severe interstitial fibrosis and tubular atrophy/loss (>50% of cortical area)    Solez K et al. Am J Transplant 2008;8:753-760 -12-

Antibody-mediated vascular rejection of kidney allografts : a population-based study (1) Identification of four distinct rejection patterns according to clinical, histological, and immunological variables The unsupervised principal component analysis examined kidney recipients with acute biopsy-proven rejection with seven variables: glomerulitis, peritubular capillaritis, donor-specific anti-HLA antibodies, C4d deposition, interstitial inflammation, tubulitis, and endarteritis. The horizontal axis opposes cellular rejection (interstitial inflammation and tubulitis) and antibody-mediated rejection (donor-specific anti-HLA antibodies, glomerulitis, peritubular capillaritis and C4d), as recognised by the international Banff classification. The vertical axis defines the presence or absence of lesions of endarteritis (appendix). -13- Lefaucheur C. et al.The Lancet 2013;381:313-319

Antibody-mediated vascular rejection of kidney allografts : a population-based study (2) Comparison of morphological and immunological variables in the four rejection patterns Bars represent SD. NS=not significant. TCMR/V– =T cell-mediated rejection without vasculitis. TCMR/V+ =T cell-mediated vascular rejection. ABMR/V+ =antibody-mediated vascular rejection. ABMR/V– =antibody-mediated rejection without vasculitis. -14- Lefaucheur C. et al.The Lancet 2013;381:313-319

Antibody-mediated vascular rejection of kidney allografts : a population-based study (3) Kaplan-Meier curves for kidney graft survival by acute rejection phenotype Initial diagnoses as per (A) Banff classifications and (B) our new approach. Graft survival in patients without rejection is purely illustrative; graft survival in these individuals starts at time of transplantation. TCMR/V– =T cell-mediated rejection without vasculitis. TCMR/V+ =T cell-mediated vascular rejection. ABMR/V– =antibody-mediated rejection without vasculitis. ABMR/V+ =antibody-mediated vascular rejection. -15- Lefaucheur C et al.The Lancet 2013;381:313-319

Antibody-mediated vascular rejection of kidney allografts : a population-based study (4) Multivariate analysis of factors associated with graft loss in patients with antibody-mediated vascular rejection, Number of patients Numbers of events Hazard ratio (95% CI) P value Intersistial inflammation and tubulitis score* 3 32 7 1 … >3 14 4.33 (1.5-12.1) 0.005 Endarteritis score <3 52 15 3 12 6 5.17 (1.8-14.6) 0.002 DSAmax MFI <3000 41 9 3000 23 3.88 (1.5-9.8) 0.004 Treatment strategy Steroids and intravenous immune globulin 13 Steroids plus munomonab-CD3 or rabbit antithymocyte globulin 29 11 0.4 (0.2-1.3) 0.1 Steroids, plasmapheresis, intravenous immune globulin, and rituximab 22 0.16 (0.04-0.66) 0.01 Hazard ratios were estimated in a single Cox proportional hazards model. DSAmax MFI=maximum mean intensity of fluorescence of donor-specific anti-HLA antibodies. *Interstitial inflammation and tubulitis score was defined as the sum of interstitial inflammation and tubulitis, and was graded from 0 to 6. -16- Lefaucheur C et al.The Lancet 2013;381:313-319

Influence of acute rejection type upon kidney allograft survival cellulaire P < 0,001 humoral Everly MJ & al. Am J Transplant. 2009;9:1063-1071 -17-

Influence of de novo DSA on kidney allograft De novo DSA at the time of acute rejection :  graft survival Rapid decrease in DSA  Improvement of allograft survival Everly MJ & al. Am J Transplant. 2009;9:1063-1071 -18-

Influence of de novo DSA at the time of acute rejection on allograft survival p= 0,001 Everly MJ & al. Am J Transplant. 2009;9:1063-1071 -19-

Diagnosis of acute rejection (1) Two situations: early posttransplant, and after a few weeks: Immediately posttransplant acuet rejection has to be ruled out in the following settings: Prolonged acute tubular necrosis (> 5 days), specially in the setting of living kidney transplant A rapid drop in urine outpout A stable but impaired serum creatinine(i,e, above the level at which it should be) An increase in serum creatinine above its baseline value Otherwise, we have to rule out acute rejection wherever there is an unexplained rise in serum creatinine. -20-

Diagnosis of acute rejection (2) Positive diagnosis: To rule-out other causes of allograft dysfunction, such as obstruction of urinary tract, or ureteral leaking, or acute pyelonephritis, or vascular thrombosis (artery or vein), or toxic levels of ciclosporin /tacrolimus Kidney allograft biopsy : Lymphocytic interstitial infiltrate (CD3 +); apply Banff classification C4d deposits? Endarteritis ? Glomerulitis? Interstitial haemorrhage and/or interstitial edema? -21-

Elementary lesions -22-

Elementary lesions Acute Glomerulitis Inflammatory infiltrate Tubulitis Capillaritis Vasculitis Chronic Chronic allograft nephropathy Interstitial fibrosis Tubular atrophy Allograft vasculopathy Arteriolar hyalinosis Others : Edema Interstitial hemorraghae C4d

Acute lesions

CD3

C4d

Diagnosis Arteritis Tubulitis + inflammatory infiltrate Capillaritis + glomerulitis + edema + C4d (+) Moderate acute rejection (grade II) Severe AR (grade III) Borderline acute rejection Grade I acute rejection (mild) Humoral rejection -36-

Differential diagnosis Infection : Acute pyelonephritis BK-virus infection Vascular problem : Arterial stenosis Venous stenosis Lymphoproliferative disorder -37-

Treatment of acute rejection First line therapy: IV Methylprednisolone: 10 mg/kg/d for 3 consecutive days = proapoptotic effect In case of steroid-resistant acute rejection (less tha 10% of cases): antilymphocyte preparations (Thymoglobulines®) In case of humoral rejection: plasmapheresis +/- IVIg +/- Rituximab (anti-CD20 monoclonal antibody) -38- 38

How to prevent acute rejection? (1) To perform pretransplant a cross-match (microlymphocytotoxicity and when possible by flow cytometry) in order to rule-out donor-specific alloantibody (ies) T-cell cross-match (assess anti-class I antibodies) B-cell cross-match (assess anti-class I and anti-class II antibodies) Dithiotrietol (DTT) which enables to get rid out of IgM alloantibodies (i,e, they are not pathogenic) -39-

How to prevent acute rejection? (2) How to perform the cross-match? By micro-lymphocytotoxicity (CDC cross-match) lymphocytes + serum + complement --> Patient’s T-cell lysis? If yes --> positive cross-match Flow cytometry Results : If T-cell cross-match is positive : NO kidney transpalntation If B-cell cross-match is positive: * transplant day serum: NO transplantation * on historical serums only: kidney transplantation IS possible but high risk of antibody-mediated rejection -40-